PEDIATRICS Vol. 94 No. 1 July 1994, pp. 132
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arroll, B.
Right arrow Articles by Thompson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arroll, B.
Right arrow Articles by Thompson, J.

Policy for Vitamin K in Newborns

Bruce Arroll MBChB1 and J. Thompson 1

1 Dept of General Practice, School of Medicine, University of Auckland, Auckland 1, New Zealand

We are writing to express our concerns about the recommendations of the Vitamin K Ad Hoc Task Force (Pediatrics 1993;91:1001-1002). Although we agree with some of their arguments, we feel that recommendation 3, which gives guidelines for using oral vitamin K, is both premature and unwarranted given the problems with the Golding et al1 paper. The design has numerous points for concern as does the interpretation because vitamin K in the United Kingdom contains three vehicles; any one of which could be the causative agent if indeed injected vitamin K does cause cancer.